Sepax Technologies Hits Record High as First-Half Profit More Than Doubles
Sepax Technologies shares rose 2.85% to a record RMB 32.07 in early trading on September 18, 2026, giving the company a total market capitalization of RMB 13.356 billion. The pharmaceutical and biotechnology sector gained 1.33%. The company reported first-half 2026 revenue of RMB 280 million, up 53.17% year on year, and net profit of RMB 111 million, up 106.19%.
In early trading on September 18, 2026, shares of Sepax Technologies hit a record high. As of 9:32, the stock was up 2.85% at RMB 32.07, with trading volume of 932,100 shares and turnover of RMB 29.5518 million, representing a turnover rate of 0.31%. The company's total A-share market capitalization reached RMB 13.356 billion, while its free-float A-share market capitalization stood at RMB 9.563 billion.
The pharmaceutical and biotechnology sector to which Sepax Technologies belongs was up 1.33% overall. Within the sector, 455 stocks advanced, with ACROBiosystems, Nanhua Bio and Berry Genomics leading the gains at 10.80%, 10.00% and 9.48% respectively. Twenty-seven stocks declined, with Kanghui Pharmaceutical, Xinganjiang and *ST Yitong falling 4.99%, 2.80% and 2.43% respectively.
Margin trading data showed that as of September 17, 2026, Sepax Technologies' margin financing and securities lending balance stood at RMB 191 million, of which the margin financing balance was RMB 190 million, down RMB 14.9405 million over the past 10 days, a month-on-month decline of 7.28%.
The company's 2026 interim report showed first-half revenue of RMB 280 million, up 53.17% year on year; net profit of RMB 111 million, up 106.19% year on year; basic earnings per share of RMB 0.2669; and a weighted average return on equity of 7.97%.